Please use this identifier to cite or link to this item: https://doi.org/10.1093/ndt/gfm468
DC FieldValue
dc.titleIs a standard fixed dose of mycophenolate mofetil ideal for all patients?
dc.contributor.authorYau, Wai-Ping
dc.contributor.authorVathsala, Anantharaman
dc.contributor.authorLou, Huei-Xin
dc.contributor.authorChan, Eli
dc.date.accessioned2022-07-29T07:07:04Z
dc.date.available2022-07-29T07:07:04Z
dc.date.issued2007-12-01
dc.identifier.citationYau, Wai-Ping, Vathsala, Anantharaman, Lou, Huei-Xin, Chan, Eli (2007-12-01). Is a standard fixed dose of mycophenolate mofetil ideal for all patients?. NEPHROLOGY DIALYSIS TRANSPLANTATION 22 (12) : 3638-3645. ScholarBank@NUS Repository. https://doi.org/10.1093/ndt/gfm468
dc.identifier.issn0931-0509
dc.identifier.issn1460-2385
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/229446
dc.description.abstractBackground. A standard fixed dose of 2 g/day of mycophenolate mofetil (MMF), irrespective of total body weight (TBW), is recommended when used in combination with cyclosporine and corticosteroids in renal transplantation. Methods. To determine the optimal MMF dose in a population with wide variation in TBW, steady-state pharmacokinetics of mycophenolic acid (MPA) was performed in 53 Asian (Chinese, Malay, Indian, Eurasian) renal transplant recipients (RTX) receiving MMF [250-1000 mg twice daily (BD)] for at least 3 months. Blood samples were collected at 0, 0.5, 1, 1.5, 2 and 6 h after the MMF dose and total MPA quantified using HPLC. Results. Drug exposure, as evaluated by AUC ss, 0-12, demonstrated a significant positive correlation with TBW-adjusted MMF dose (outliers omitted: r2 = 0.49, P < 0.0005). An AUCss, 0-12 of 45 mg h/l could be attained with an MMF dose of 12 mg/kg BD. Conclusion. This study proposes that MMF should be dosed based on TBW rather than a fixed dose regimen in RTX. © The Author [2007]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
dc.language.isoen
dc.publisherOXFORD UNIV PRESS
dc.sourceElements
dc.subjectScience & Technology
dc.subjectLife Sciences & Biomedicine
dc.subjectTransplantation
dc.subjectUrology & Nephrology
dc.subjectAsian
dc.subjectcyclosporine
dc.subjectmycophenolic acid
dc.subjectpharmacokinetics
dc.subjectrenal transplant
dc.subjectweight-adjusted dosing
dc.subjectRENAL-TRANSPLANT RECIPIENTS
dc.subjectPHARMACOKINETIC-PHARMACODYNAMIC RELATIONSHIP
dc.subjectALLOGRAFT RECIPIENTS
dc.subjectRANDOMIZED-TRIAL
dc.subjectACUTE REJECTION
dc.subjectCALCINEURIN INHIBITORS
dc.subjectKIDNEY-TRANSPLANTATION
dc.subjectTROUGH LEVELS
dc.subjectGLUCURONIDE METABOLITE
dc.subjectDIFFERENT DOSAGES
dc.typeArticle
dc.date.updated2022-07-23T13:24:46Z
dc.contributor.departmentMEDICINE
dc.contributor.departmentPHARMACY
dc.description.doi10.1093/ndt/gfm468
dc.description.sourcetitleNEPHROLOGY DIALYSIS TRANSPLANTATION
dc.description.volume22
dc.description.issue12
dc.description.page3638-3645
dc.description.placeUNITED KINGDOM
dc.published.statePublished
Appears in Collections:Staff Publications
Elements

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
WaiPing_FixedDosing of Mycophenolate_NDT2007.pdf230.37 kBAdobe PDF

CLOSED

Published

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.